Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GYRE
Upturn stock ratingUpturn stock rating

Gyre Therapeutics Inc. (GYRE)

Upturn stock ratingUpturn stock rating
$8.07
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/20/2025: GYRE (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $20

1 Year Target Price $20

Analysts Price Target For last 52 week
$20Target price
Low$6.11
Current$8.07
high$19

Analysis of Past Performance

Type Stock
Historic Profit 23.61%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 670.20M USD
Price to earnings Ratio 371
1Y Target Price 20
Price to earnings Ratio 371
1Y Target Price 20
Volume (30-day avg) 1
Beta -
52 Weeks Range 6.11 - 19.00
Updated Date 06/30/2025
52 Weeks Range 6.11 - 19.00
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.02

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-06-12
When After Market
Estimate 0.03
Actual 0.0043

Profitability

Profit Margin 7.21%
Operating Margin (TTM) 10.31%

Management Effectiveness

Return on Assets (TTM) 5.18%
Return on Equity (TTM) 12.12%

Valuation

Trailing PE 371
Forward PE -
Enterprise Value 640989378
Price to Sales(TTM) 6.66
Enterprise Value 640989378
Price to Sales(TTM) 6.66
Enterprise Value to Revenue 6.37
Enterprise Value to EBITDA 52.8
Shares Outstanding 90323296
Shares Floating 19717013
Shares Outstanding 90323296
Shares Floating 19717013
Percent Insiders 91.25
Percent Institutions 2.99

Analyst Ratings

Rating 1
Target Price 20
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Gyre Therapeutics Inc.

stock logo

Company Overview

overview logo History and Background

Gyre Therapeutics, Inc. focuses on developing and commercializing innovative therapies for liver diseases. The company's history reflects a commitment to addressing unmet medical needs in hepatology, with milestones including preclinical and clinical development of proprietary drug candidates.

business area logo Core Business Areas

  • Liver Disease Therapeutics: Development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver-related conditions.

leadership logo Leadership and Structure

Specific leadership details and organizational structure are not readily available in provided context but generally include a CEO, CFO, research and development leadership, and a board of directors.

Top Products and Market Share

overview logo Key Offerings

  • F351: Gyre Therapeutics' lead drug candidate, F351, is a small molecule therapeutic designed to target fibrosis in NASH. Market share data is currently unavailable as the product is in clinical development. Competitors include Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX) who are also in the NASH space.

Market Dynamics

industry overview logo Industry Overview

The liver disease therapeutics market, especially for NASH, is rapidly growing due to the increasing prevalence of obesity and diabetes globally.

Positioning

Gyre Therapeutics is positioning itself as a key player in the NASH therapeutics market with its F351 candidate, focusing on novel mechanisms of action.

Total Addressable Market (TAM)

The NASH market is projected to reach tens of billions of dollars. Gyre Therapeutics aims to capture a significant portion of this market with successful clinical development and commercialization of F351.

Upturn SWOT Analysis

Strengths

  • Proprietary drug candidate targeting NASH
  • Focus on fibrosis resolution
  • Experienced management team (assumed)

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Dependence on successful clinical trials
  • Currently no marketed products

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into other liver disease indications
  • Positive clinical trial results

Threats

  • Competition from other NASH therapeutics developers
  • Regulatory hurdles
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • MDGL
  • VKTX
  • GILD

Competitive Landscape

Gyre Therapeutics competes with larger, more established pharmaceutical companies in the NASH market. Its advantage lies in its unique therapeutic approach.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data unavailable.

Future Projections: Future growth depends on the successful development and commercialization of F351 and is highly speculative at this point.

Recent Initiatives: Focus on advancing F351 through clinical trials.

Summary

Gyre Therapeutics is a development-stage company focused on innovative liver disease therapeutics, particularly NASH. Its success hinges on the clinical development of F351. The company faces significant competition and financial constraints but has the potential for substantial growth if its lead candidate proves effective. Keeping a close watch on Clinical Trial results will determine the company's success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings (unavailable)
  • Industry Reports

Disclaimers:

This analysis is based on limited publicly available information and should not be considered financial advice. Market share data is estimated and subject to change. Please consult a financial professional before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Gyre Therapeutics Inc.

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2006-04-12
CEO & Director Dr. Han Ying Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 579
Full time employees 579

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.